Natural variation of equine infectious anemia virus Gag protein cytotoxic T lymphocyte epitopes.

This research studied the variability of two specific epitopes (parts of an antigen recognized by the immune system) of the equine infectious anemia virus (EIAV) in different strains of the virus. It found variations in both epitopes across these strains, and also discovered a significant degree of variation in the Gag proteins of a newly-isolated strain. No variation affecting immune recognition was observed in a horse infected multiple times. The findings imply that immune recognition in this horse might involve epitopes other than the two studied in this research.

Background

• The research focuses on studying equine infectious anemia virus (EIAV), a viral disease in horses that affects their immune system and blood cells, causing symptoms such as anemia, fever, and weight loss.
• The specific components studied from the virus are the cytotoxic T lymphocyte (CTL) epitopes, regions on an antigen that are recognized by CTLs, immune cells that kill infected host cells.
• Specific attention is given to two epitopes, known as epitope 18a and epitope 28b-1, which are specific to two different horse leukocyte alloantigens (HLA), ELA-A5.1 and ELA-A9 respectively. ELA stands for Equine Leukocyte Antigen, a system of cell surface proteins involved in immune response in horses.

Findings

• The researchers found variations in both the CTL epitopes 18a and 28b-1 in three different wild strains of EIAV. This reveals that these epitopes are not universally similar or conserved in all EIAV strains.
• The research also discovered significant variations, about a 12% amino acid change, in the Gag proteins of a newly isolated strain of EIAV. The Gag protein is an essential protein for the virus, involved in virus assembly and release.
• When the team investigated epitope 18a in two virus isolates from a single horse (named H513), that had sequential disease episodes, no variation that could affect immune recognition was found.
• They also noted changes in the horse’s immunity over time in relation to epitope 18a, with immune responses being present before and absence of disease episodes later associated with an increased immune response, though not to epitope 18a.

Implications

• The findings of the research suggest that there is a level of variability in the epitopes of the EIAV virus across different strains, which could have implications for vaccine development.
• The lack of variation in epitope 18a in a single horse over the course of infection and disease suggests that this epitope may not be the primary target of the immune system for EIAV in this context.
• The increased immune response noted in the later infection stages in the horse, despite not being directed at epitope 18a, potentially represents recognition of other unaffected epitopes, implying the immune system can maintain the carrier state by recognizing multiple epitopes.